HAWTHORNE, N.Y. (AP) — Biotechnology company Acorda Therapeutics said Tuesday the FDA has confirmed an Oct. 14 committee review of the multiple sclerosis treatment Fampridine-SR. The agency’s Peripheral and Central Nervous System Drugs Advisory Committee will review Acorda’s new drug application. The FDA had accepted the application in May, granted it priority review status and set Oct. 22 as a target date to complete the review. Acorda also said Tuesday the FDA granted preliminary approval for the trade name Amayafrom. Fampridine-SR is designed to improve walking ability in people with multiple sclerosis.